Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity

Dayanira Alsina-Beauchamp, Alejandra Escós, Pilar Fajardo, Diego González-Romero, Ester Díaz-Mora, Ana Risco, Miguel A. Martín-Serrano, Carlos del Fresno, Jorge Dominguez-Andrés, Noelia Aparicio, Rafal Zur, Natalia Shpiro, Gordon D. Brown, Carlos Ardavín, Mihai G. Netea, Susana Alemany, Juan J. Sanz-Ezquerro, Ana Cuenda

Research output: Contribution to journalArticle

2 Citations (Scopus)
5 Downloads (Pure)

Abstract

Candida albicans is a frequent etiologic agent of sepsis associated with high mortality in immunocompromised patients. Developing new antifungal therapies is a medical need due to the low efficiency and resistance to current antifungal drugs. Here, we show that p38J and p38G regulate the innate immune response to C. albicans. We describe a new TAK1-TPL2-MKK1-ERK1/2 pathway in macrophages, which is activated by Dectin-1 engagement and positively regulated by p38J/p38G. In mice, p38J/p38G deficiency protects against C. albicans infection by increasing ROS and iNOS production and thus the antifungal capacity of neutrophils and macrophages, and by decreasing the hyper-inflammation that leads to severe host damage. Leucocyte recruitment to infected kidneys and production of inflammatory mediators are decreased in p38J/G null mice, reducing septic shock. p38J/p38G in myeloid cells are critical for this effect. Moreover, pharmacological inhibition of p38J/p38G in mice reduces fungal burden, revealing that these p38MAPKs may be therapeutic targets for treating C. albicans infection in humans.
Original languageEnglish
Article numbere8485
JournalEMBO Molecular Medicine
Volume10
Issue number5
Early online date16 Apr 2018
DOIs
Publication statusPublished - May 2018

Fingerprint

Candidiasis
Myeloid Cells
Candida albicans
Immunity
Macrophages
MAP Kinase Signaling System
Immunocompromised Host
Septic Shock
Infection
Innate Immunity
Sepsis
Neutrophils
Leukocytes
Pharmacology
Inflammation
Kidney
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • p38MAPK
  • signalling
  • infection
  • Candida albicans
  • Kinase inhibitor

Cite this

Alsina-Beauchamp, D., Escós, A., Fajardo, P., González-Romero, D., Díaz-Mora, E., Risco, A., ... Cuenda, A. (2018). Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity. EMBO Molecular Medicine, 10(5), [e8485]. https://doi.org/10.15252/emmm.201708485

Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity. / Alsina-Beauchamp, Dayanira; Escós, Alejandra; Fajardo, Pilar; González-Romero, Diego; Díaz-Mora, Ester; Risco, Ana; Martín-Serrano, Miguel A.; Fresno, Carlos del; Dominguez-Andrés, Jorge; Aparicio, Noelia; Zur, Rafal; Shpiro, Natalia; Brown, Gordon D.; Ardavín, Carlos; Netea, Mihai G.; Alemany, Susana; Sanz-Ezquerro, Juan J.; Cuenda, Ana.

In: EMBO Molecular Medicine, Vol. 10, No. 5, e8485, 05.2018.

Research output: Contribution to journalArticle

Alsina-Beauchamp, D, Escós, A, Fajardo, P, González-Romero, D, Díaz-Mora, E, Risco, A, Martín-Serrano, MA, Fresno, CD, Dominguez-Andrés, J, Aparicio, N, Zur, R, Shpiro, N, Brown, GD, Ardavín, C, Netea, MG, Alemany, S, Sanz-Ezquerro, JJ & Cuenda, A 2018, 'Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity', EMBO Molecular Medicine, vol. 10, no. 5, e8485. https://doi.org/10.15252/emmm.201708485
Alsina-Beauchamp D, Escós A, Fajardo P, González-Romero D, Díaz-Mora E, Risco A et al. Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity. EMBO Molecular Medicine. 2018 May;10(5). e8485. https://doi.org/10.15252/emmm.201708485
Alsina-Beauchamp, Dayanira ; Escós, Alejandra ; Fajardo, Pilar ; González-Romero, Diego ; Díaz-Mora, Ester ; Risco, Ana ; Martín-Serrano, Miguel A. ; Fresno, Carlos del ; Dominguez-Andrés, Jorge ; Aparicio, Noelia ; Zur, Rafal ; Shpiro, Natalia ; Brown, Gordon D. ; Ardavín, Carlos ; Netea, Mihai G. ; Alemany, Susana ; Sanz-Ezquerro, Juan J. ; Cuenda, Ana. / Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity. In: EMBO Molecular Medicine. 2018 ; Vol. 10, No. 5.
@article{d0688134f91243918cbde8e43e13d050,
title = "Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity",
abstract = "Candida albicans is a frequent etiologic agent of sepsis associated with high mortality in immunocompromised patients. Developing new antifungal therapies is a medical need due to the low efficiency and resistance to current antifungal drugs. Here, we show that p38J and p38G regulate the innate immune response to C. albicans. We describe a new TAK1-TPL2-MKK1-ERK1/2 pathway in macrophages, which is activated by Dectin-1 engagement and positively regulated by p38J/p38G. In mice, p38J/p38G deficiency protects against C. albicans infection by increasing ROS and iNOS production and thus the antifungal capacity of neutrophils and macrophages, and by decreasing the hyper-inflammation that leads to severe host damage. Leucocyte recruitment to infected kidneys and production of inflammatory mediators are decreased in p38J/G null mice, reducing septic shock. p38J/p38G in myeloid cells are critical for this effect. Moreover, pharmacological inhibition of p38J/p38G in mice reduces fungal burden, revealing that these p38MAPKs may be therapeutic targets for treating C. albicans infection in humans.",
keywords = "p38MAPK, signalling, infection, Candida albicans, Kinase inhibitor",
author = "Dayanira Alsina-Beauchamp and Alejandra Esc{\'o}s and Pilar Fajardo and Diego Gonz{\'a}lez-Romero and Ester D{\'i}az-Mora and Ana Risco and Mart{\'i}n-Serrano, {Miguel A.} and Fresno, {Carlos del} and Jorge Dominguez-Andr{\'e}s and Noelia Aparicio and Rafal Zur and Natalia Shpiro and Brown, {Gordon D.} and Carlos Ardav{\'i}n and Netea, {Mihai G.} and Susana Alemany and Sanz-Ezquerro, {Juan J.} and Ana Cuenda",
note = "Fundaci{\'o} la Marat{\'o} de TV3 (GrantNumber(s): 20133431; Grant recipient(s): Ana Cuenda) Wellcome Trust (GrantNumber(s): 97377, 102705; Grant recipient(s): GORDON D. BROWN) Ministerio de Econom{\'i}a y Competitividad (GrantNumber(s): SAF2016-79792-R, SAF2014- 52009-R, SAF2013-45331-R; Grant recipient(s): Ana Cuenda, SUSANA ALEMANY) Medical Research Council (GrantNumber(s): MR/N006364/1; Grant recipient(s): GORDON D. BROWN) ERC Consolidator Grant (GrantNumber(s): 310372; Grant recipient(s): Mihai Netea)",
year = "2018",
month = "5",
doi = "10.15252/emmm.201708485",
language = "English",
volume = "10",
journal = "EMBO Molecular Medicine",
issn = "1757-4684",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity

AU - Alsina-Beauchamp, Dayanira

AU - Escós, Alejandra

AU - Fajardo, Pilar

AU - González-Romero, Diego

AU - Díaz-Mora, Ester

AU - Risco, Ana

AU - Martín-Serrano, Miguel A.

AU - Fresno, Carlos del

AU - Dominguez-Andrés, Jorge

AU - Aparicio, Noelia

AU - Zur, Rafal

AU - Shpiro, Natalia

AU - Brown, Gordon D.

AU - Ardavín, Carlos

AU - Netea, Mihai G.

AU - Alemany, Susana

AU - Sanz-Ezquerro, Juan J.

AU - Cuenda, Ana

N1 - Fundació la Marató de TV3 (GrantNumber(s): 20133431; Grant recipient(s): Ana Cuenda) Wellcome Trust (GrantNumber(s): 97377, 102705; Grant recipient(s): GORDON D. BROWN) Ministerio de Economía y Competitividad (GrantNumber(s): SAF2016-79792-R, SAF2014- 52009-R, SAF2013-45331-R; Grant recipient(s): Ana Cuenda, SUSANA ALEMANY) Medical Research Council (GrantNumber(s): MR/N006364/1; Grant recipient(s): GORDON D. BROWN) ERC Consolidator Grant (GrantNumber(s): 310372; Grant recipient(s): Mihai Netea)

PY - 2018/5

Y1 - 2018/5

N2 - Candida albicans is a frequent etiologic agent of sepsis associated with high mortality in immunocompromised patients. Developing new antifungal therapies is a medical need due to the low efficiency and resistance to current antifungal drugs. Here, we show that p38J and p38G regulate the innate immune response to C. albicans. We describe a new TAK1-TPL2-MKK1-ERK1/2 pathway in macrophages, which is activated by Dectin-1 engagement and positively regulated by p38J/p38G. In mice, p38J/p38G deficiency protects against C. albicans infection by increasing ROS and iNOS production and thus the antifungal capacity of neutrophils and macrophages, and by decreasing the hyper-inflammation that leads to severe host damage. Leucocyte recruitment to infected kidneys and production of inflammatory mediators are decreased in p38J/G null mice, reducing septic shock. p38J/p38G in myeloid cells are critical for this effect. Moreover, pharmacological inhibition of p38J/p38G in mice reduces fungal burden, revealing that these p38MAPKs may be therapeutic targets for treating C. albicans infection in humans.

AB - Candida albicans is a frequent etiologic agent of sepsis associated with high mortality in immunocompromised patients. Developing new antifungal therapies is a medical need due to the low efficiency and resistance to current antifungal drugs. Here, we show that p38J and p38G regulate the innate immune response to C. albicans. We describe a new TAK1-TPL2-MKK1-ERK1/2 pathway in macrophages, which is activated by Dectin-1 engagement and positively regulated by p38J/p38G. In mice, p38J/p38G deficiency protects against C. albicans infection by increasing ROS and iNOS production and thus the antifungal capacity of neutrophils and macrophages, and by decreasing the hyper-inflammation that leads to severe host damage. Leucocyte recruitment to infected kidneys and production of inflammatory mediators are decreased in p38J/G null mice, reducing septic shock. p38J/p38G in myeloid cells are critical for this effect. Moreover, pharmacological inhibition of p38J/p38G in mice reduces fungal burden, revealing that these p38MAPKs may be therapeutic targets for treating C. albicans infection in humans.

KW - p38MAPK

KW - signalling

KW - infection

KW - Candida albicans

KW - Kinase inhibitor

U2 - 10.15252/emmm.201708485

DO - 10.15252/emmm.201708485

M3 - Article

VL - 10

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4684

IS - 5

M1 - e8485

ER -